Walgreens Boots Alliance, Inc.

Walgreens divests 12,000,000 BTSG shares at $21.16, reducing stake to 51.6%, following 57.14% well-timed sell pattern.

Walgreens Boots Alliance sold 12,000,000 shares of BrightSpring Health Services at $21.16 on 2025-02-18, cutting its stake from 23,239,996 to 11,239,996 shares (a 51.6% reduction in holdings). The sale price of $21.16 sits within BrightSpring's 52-week range of $8.23–$24.24, only 1.3% below the 52-week high and 3.7% above the current price of $20.40. Across Walgreens' cross-ticker track record, prior sell transactions have been well-timed 57.14% of the time, with an average 90-day post-sale return of +3.9%, indicating that when Walgreens sells, the stock typically has already moved past its local peak. The timing of this exit—at near-52-week highs while the company carries negative net income ($-8,230,000.00 on quarterly revenue of $2,906,823,000.00)—mirrors the insider's historical pattern of exiting near peaks.

Walgreens (10% owner) sells 1,286,376 shares of Cencora at $244.51 for $314.5M, reducing stake to 12.57M shares.

Walgreens divested 1,286,376 shares in 2 separate transactions on 2025-02-06, netting $314,531,795.76 at a blended average price of $244.51, reducing its post-transaction holdings to 12.57M shares from 13.86M shares (a -9.3% reduction). The sale occurred at $244.51 while the current market price stands at $246.38, placing the transactions near recent highs within the 52-week range of $216.21–$258.46. Examining Walgreens' prior transaction history at Cencora reveals mixed timing outcomes: 2 of 4 prior sales achieved well-timed 90-day exits (negative post-sale returns), while the other 2 saw the stock appreciate after the sale. The cross-ticker track record shows a 57.14% well-timed rate on prior sells with an average 90-day return of +3.9%, suggesting modest success in sale timing overall. At current market conditions—with COR trading near its 52-week highs, posting $81.5B in latest quarterly revenue and 12.1% annual growth, and valued at a P/E of 34.22—this divestment warrants close attention to whether it reflects a planned portfolio shift by the major shareholder or precedes a change in conviction toward the position.

Walgreens (10% owner) sold 4,438,171 shares of COR for $1.1B on 2024-08-01, reducing stake to 19.98M shares (-18.2%)

Walgreens Boots Alliance divested 4,438,171 shares of Cencora at $240.56 per share for $1,067,646,415.76, a substantial reduction of its 10% stake. The sale occurred when Cencora shares were near the 52-week range ($172.87–$247.57) and represents a deliberate lightening of the position post-transaction holdings at 19.98M shares. In context of Walgreens' cross-ticker track record, prior sales have averaged a 30-day return of +3.2% and 90-day return of +4.2%, with 60.00% well-timed at the 90-day mark—indicating the insider has historically sold before subsequent gains. At this specific ticker (Cencora), Walgreens has 3 prior sales: the most recent (2024-05-22) posted +10.0% in 30 days; the 2024-02-07 sale saw only +0.9% in 30 days and -3.7% in 90 days; and the 2023-11-09 sale returned +3.3% in 30 days and +21.6% in 90 days. The timing pattern at Cencora shows 1 of 2 prior measurable 90-day sales were well-timed, mixed relative to the cross-ticker average of 60%. Investors should track whether this August 2024 sale follows that pattern or diverges as Cencora (P/E 25.61, revenue growth +9.9% YoY) continues forward.